Immunopeptidomics Profiling of Healthy Tissue Matched to Primary and Metastatic Tumor Samples

Therapeutic peptide-based vaccination is a promising strategy for cancer immunotherapies. The identification of tumor-specific antigens is key to developing therapies. Mass spectrometry has emerged as the primary technique for the identification of peptides presented on human leukocyte antigen (HLA), i.e., immunopeptides. While tremendous progress has been made, the analysis of immunopeptides remains challenging. This is especially true in a clinical context where tissue material is scarce, often limited to a handful of biopsies, with amounts below 20mg. Here, we introduce a workflow that allows deep immunopeptidomics profiling of clinically relevant samples.